NCT06335160

Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

Clinical Study to Evaluate the Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine

Detailed description

A randomized, controlled, and parallel study will comprise 46 patients with UC. Patients will be recruited from GastroEnterology Department, Mansoura University Hospital. The participants will be randomly assigned into two groups as follow: Group 1: control group (Mesalamine group, n =23) who will receive 1 g mesalamine three times daily for 6 months. Group 2: (mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months.

Conditions

• Ulcerative Colitis

Interventions

Type	Name	Description
DRUG	Mebendazole	mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months

Timeline

• Start date: 2024-04-20
• Primary completion: 2026-04-01
• Completion: 2026-05-01
• First posted: 2024-03-28
• Last updated: 2026-02-06

Locations

1 site across 1 country: Egypt